Reducing the PAINS in High Throughput Screening: Assay design as a tool for maximising efficiency By Dr Philip S. Jones and Dr Stuart P. McElroy While the quality of the compound collection is frequently described as a key determinant of the success of a high throughput screening campaign, in our… Read More
Optimising Phenotypic Screening - Single-cell analysis versus 3D multicell analysis By Dr Richard M. Eglen In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is based on the… Read More
Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this… Read More
2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to look ahead, to… Read More
Fail Early, Fail Fast - A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al. New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies using complex biological assays,… Read More
Automating Automation - How close are we to Artificial Intelligence impact? By Dr Michael A. Tarselli, Dr Yohann Potier and Dr Alan E. Fletcher In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that emerging from automated… Read More
Automated Cell-based Assays: Novel tools overcome the barriers to drug discovery success By Helen Stewart-Miller and Kate Tointon In this article, we look at how commercial products and services are facilitating the automation of cell-based assays to advance drug discovery and accelerate the delivery of new medicines to patients. Cell-based… Read More
Safety First - Automating cell line development By Jon Newman-Smith Developing and maintaining cell cultures in a stable and sterile environment is of paramount importance to protect samples and increase overall success of drug discovery pipelines. Cell lines are extremely fragile and susceptible to contamination which can be catastrophic in… Read More
Flow Cytometry - The advanced systems overcoming drug discovery pain points By Helen Stewart-Miller and Dr Richard Massey Flow cytometry is an invaluable technique for the characterisation of highly heterogeneous cell populations. Thanks to improvements in throughput, automation and multichannel detection capabilities, recent years have seen its use expand across… Read More
How Mergers and Acquisitions Will Drive Oncology Research in 2019 By Dr Michael Seiler 2019 got off to a fast start for oncology drug discovery, with numerous mergers, acquisitions and collaborations announced in quick succession. These ventures provide a window into key trends in oncology research, where investigators are likely… Read More
From Genotype to Phenotype: Leveraging functional genomics in oncology By Dr Menelas Pangalos & Steve Rees et al. A challenge in drug discovery is that, at best, only around one in five drug candidates will lead to the launch of a medicine. In 2011, AstraZeneca initiated a strategic ‘5R Framework’… Read More
3D Organoid Cell Culture - Optimising disease models for research and drug discovery By Dr Amanda Linkous, Hilary Sherman, Iris Li and Dr Richard M. Eglen The use of human-induced pluripotent stem cells (HiPSCs) continues to grow in three-dimensional (3D) spheroid and organoid culture. Although advances in 3D cell culture… Read More
Systems Pharmacology: When multi-targeting is advantageous By Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor The safety and efficacy of therapeutic drugs still requires improvement. In part this is due to the promiscuity of individual drugs, which on average can interact with an estimated 6-28… Read More
The Growth of Organoids in Cancer Drug Discovery By Dr J. Mark Treherne, et al., Will the automated expansion of organoids help improve the productivity of cancer drug discovery? Increasingly, complex cell-based assays and tissues are routinely used as part of cancer drug discovery. However, conventional monolayer or suspension cultures… Read More
Increasing Drug Discovery Success With 3D Cell Culture Systems By Dr Richard M. Eglen, Dr Feng Li and Dr Tony Frutos Drug candidates often fail in the clinic for two reasons: they lack efficacy or possess an adverse toxicity profile. These failures can come at a high cost, especially when… Read More
How Advanced Automated Liquid Handling Systems are Reshaping Drug Discovery By Helen Stewart-Miller and Dr Richard Massey Winter 2018/19 Once the domain of high-throughput screening (HTS) applications, automated liquid handling systems are now used ubiquitously in drug discovery and have been fundamental in increasing throughput, driving efficiencies and improving standards… Read More